This course focuses on early-stage biotechnology companies, with particular emphasis on understanding the underlying science, technology, and disease targets—together with the application of novel business structures and financing methods—to facilitate drug discovery, clinical development, and greater patient access to new therapies. Current research is enhancing our understanding of the genetic, molecular, and cellular bases of many human diseases, and is leading to many new types of biotherapeutics that we will cover in this course, including recombinant therapeutic proteins; monoclonal antibodies and antibody drug conjugates; cancer immunotherapies, replacement cells and genetically engineered cells; and nucleic acid and gene therapies. Translating these discoveries into drugs and diagnostics increasingly requires the establishment of for-profit companies, but funding for early-stage development of novel therapies is becoming scarcer, especially for therapeutics for “rare” diseases that affect small populations. The dearth of funding for early-stage biotherapeutics companies in the so-called “Valley of Death” can be attributed to several factors, but a common thread is increasing financial risks in the biopharma industry and greater uncertainty surrounding the scientific, medical, economic, political, and academic environments within the biomedical ecosystem. Increasing risk and uncertainty inevitably leads to an outflow of capital as investors and other stakeholders seek more attractive opportunities in other industries. By applying financial techniques such as portfolio theory, securitization, and derivative securities to biomedical contexts, more efficient business and funding structures can be developed to reduce financial risks, lower the cost of capital, and bring more life-saving therapies to patients faster. Thus this course will also cover basic financial analysis for the life-sciences professional; the historical financial risks and returns of the biotech and pharmaceutical industries; the evaluation of the science and business potential as well as the mechanics of financing biotech startups; capital budgeting for biopharmaceutical companies; and applications of financial engineering in drug royalty investment companies, biomedical megafunds, drug approval swaps, and life sciences investment banking.
An excellent online course offered by edX: how it works
edX courses consist of weekly learning sequences. Each learning sequence is composed of short videos interspersed with interactive learning exercises, where students can immediately practise the concepts from the videos. The courses often include tutorial videos that are similar to small on-campus discussion groups, an online textbook, and an online discussion forum where students can post and review questions and comments to each other and teaching assistants. Where applicable, online laboratories are incorporated into the course.
edX offers certificates of successful completion and some courses are credit-eligible. Whether or not a college or university offers credit for an online course is within the sole discretion of the school. edX offers a variety of ways to take courses, including verified courses where students have the option to audit the course (no cost) or to work toward an edX Verified Certificate (fees vary by course). edX also offers XSeries Certificates for completion of a bundled set of two to seven verified courses in a single subject (cost varies depending on the courses).
An edX learning programme under Other Experiences